As the SARS-CoV-2 inhibitors described above were identified by a multi-target host-based entry targets screening, their ability to interfere with SARS-CoV-2 entry was evaluated in a surrogate model of infection based on retroviral vectors pseudotyped with SARS-CoV-2 Spike envelope glycoprotein. Here, ERVW-1 is linked to infection.